BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 37156839)

  • 1. Targeting MFAP5 in cancer-associated fibroblasts sensitizes pancreatic cancer to PD-L1-based immunochemotherapy via remodeling the matrix.
    Duan Y; Zhang X; Ying H; Xu J; Yang H; Sun K; He L; Li M; Ji Y; Liang T; Bai X
    Oncogene; 2023 Jun; 42(25):2061-2073. PubMed ID: 37156839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.
    Koikawa K; Kibe S; Suizu F; Sekino N; Kim N; Manz TD; Pinch BJ; Akshinthala D; Verma A; Gaglia G; Nezu Y; Ke S; Qiu C; Ohuchida K; Oda Y; Lee TH; Wegiel B; Clohessy JG; London N; Santagata S; Wulf GM; Hidalgo M; Muthuswamy SK; Nakamura M; Gray NS; Zhou XZ; Lu KP
    Cell; 2021 Sep; 184(18):4753-4771.e27. PubMed ID: 34388391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: Challenges and opportunities.
    Qin Q; Yu R; Eriksson JE; Tsai HI; Zhu H
    Cancer Lett; 2024 Jun; 591():216859. PubMed ID: 38615928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer.
    McAndrews KM; Chen Y; Darpolor JK; Zheng X; Yang S; Carstens JL; Li B; Wang H; Miyake T; Correa de Sampaio P; Kirtley ML; Natale M; Wu CC; Sugimoto H; LeBleu VS; Kalluri R
    Cancer Discov; 2022 Jun; 12(6):1580-1597. PubMed ID: 35348629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
    Liu H; Shi Y; Qian F
    Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer.
    Yeung TL; Leung CS; Yip KP; Sheng J; Vien L; Bover LC; Birrer MJ; Wong STC; Mok SC
    Clin Cancer Res; 2019 Nov; 25(21):6417-6428. PubMed ID: 31332047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAFs-derived MFAP5 promotes bladder cancer malignant behavior through NOTCH2/HEY1 signaling.
    Zhou Z; Cui D; Sun MH; Huang JL; Deng Z; Han BM; Sun XW; Xia SJ; Sun F; Shi F
    FASEB J; 2020 Jun; 34(6):7970-7988. PubMed ID: 32293074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins abrogate gemcitabine-induced PD-L1 expression in pancreatic cancer-associated fibroblasts and cancer cells with improved therapeutic outcome.
    Minz AP; Mohapatra D; Dutta M; Sethi M; Parida D; Mohapatra AP; Mishra S; Kar S; Sasmal PK; Senapati S
    Cancer Immunol Immunother; 2023 Dec; 72(12):4261-4278. PubMed ID: 37926727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer.
    Yu Y; Schuck K; Friess H; Kong B
    Expert Opin Ther Targets; 2021 Jan; 25(1):5-13. PubMed ID: 33246383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
    Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
    Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Tango between Cancer-Associated Fibroblasts (CAFs) and Immune Cells in Affecting Immunotherapy Efficacy in Pancreatic Cancer.
    Stouten I; van Montfoort N; Hawinkels LJAC
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
    Zhang L; Yao J; Li W; Zhang C
    Oncol Res; 2018 Jul; 26(6):827-835. PubMed ID: 28477403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer.
    Lefler JE; MarElia-Bennett CB; Thies KA; Hildreth BE; Sharma SM; Pitarresi JR; Han L; Everett C; Koivisto C; Cuitino MC; Timmers CD; O'Quinn E; Parrish M; Romeo MJ; Linke AJ; Hobbs GA; Leone G; Guttridge DC; Zimmers TA; Lesinski GB; Ostrowski MC
    Life Sci Alliance; 2022 Nov; 5(11):. PubMed ID: 35803738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precise Photodynamic Therapy by Midkine Nanobody-Engineered Nanoparticles Remodels the Microenvironment of Pancreatic Ductal Adenocarcinoma and Potentiates the Immunotherapy.
    Qu C; Yuan H; Tian M; Zhang X; Xia P; Shi G; Hou R; Li J; Jiang H; Yang Z; Chen T; Li Z; Wang J; Yuan Y
    ACS Nano; 2024 Feb; 18(5):4019-4037. PubMed ID: 38253029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desmoplastic Crosstalk in Pancreatic Ductal Adenocarcinoma Is Reflected by Different Responses of Panc-1, MIAPaCa-2, PaTu-8902, and CAPAN-2 Cell Lines to Cancer-associated/Normal Fibroblasts.
    Novák Š; Kolář M; Szabó A; Vernerová Z; Lacina L; Strnad H; Šáchová J; Hradilová M; Havránek J; Španko M; Čoma M; Urban L; Kaňuchová M; Melegová N; Gürlich R; Dvořák J; Smetana K; Gál P; Szabo P
    Cancer Genomics Proteomics; 2021; 18(3):221-243. PubMed ID: 33893076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-associated fibroblasts in the invasive tumour front promote the metastasis of oral squamous cell carcinoma through MFAP5 upregulation.
    Wang Y; Wang R; Li B; Huang Z; Zhao S; Chen S; Lan T; Ren S; Wu F; Tan J; Li J
    Gene; 2023 Aug; 876():147504. PubMed ID: 37217152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential.
    Knudsen ES; Balaji U; Freinkman E; McCue P; Witkiewicz AK
    Oncotarget; 2016 Nov; 7(48):78396-78411. PubMed ID: 27623078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors.
    Djurec M; Graña O; Lee A; Troulé K; Espinet E; Cabras L; Navas C; Blasco MT; Martín-Díaz L; Burdiel M; Li J; Liu Z; Vallespinós M; Sanchez-Bueno F; Sprick MR; Trumpp A; Sainz B; Al-Shahrour F; Rabadan R; Guerra C; Barbacid M
    Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1147-E1156. PubMed ID: 29351990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nano-Econazole Enhanced PD-L1 Checkpoint Blockade for Synergistic Antitumor Immunotherapy against Pancreatic Ductal Adenocarcinoma.
    Li Q; Qin S; Tian H; Liu R; Qiao L; Liu S; Li B; Yang M; Shi J; Nice EC; Li J; Lang T; Huang C
    Small; 2023 Jun; 19(23):e2207201. PubMed ID: 36899444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.